To help support you and your practice, we've updated our site with important

The only T2D therapy approved by the FDA to reduce the risk of end-stage kidney disease, doubling of serum creatinine, cardiovascular death, and hospitalization for heart failure in adults who have T2D and diabetic nephropathy with albuminuria >300 mg/day1

In adults with DKD* and T2D,

INVOKANA® 100 mg is the only SGLT2i proven to deliver all of the following:

Magenta circle with a white pair of kidneys inside

Reduced progression of DKD1

30% RRR in primary composite outcome of end-stage kidney disease, doubling of serum creatinine, and renal or CV death.5

Magenta circle with a white heart inside

Reduced risk of hospitalization for heart failure1

39% RRR§ in hospitalization for heart failure.6

Magenta circle with a white cross inside

Proven safety profile in patients with an eGFR of 30 to <901

  • Similar overall AEs with INVOKANA® vs placebo (35.1 vs 37.9 per 100 patient-years), except for DKA and male GMI. No imbalance in fracture or amputation. Hypotension incidence was 2.8% vs 1.5%, respectively. Hypoglycemia incidence was 4.43 vs 4.89 per 100 patient-years, respectively1,5||
  • INVOKANA® 100 mg can be initiated in patients with an eGFR as low as 30.* Patients already on INVOKANA® whose eGFR declines below 30* can continue on the 100-mg dose unless dialysis is initiated1
  • INVOKANA® is contraindicated in patients on dialysis

eGFR is measured in mL/min/1.73 m 2.
*With albuminuria >300 mg/day.
End-stage kidney disease was defined as dialysis for ≥30 days, kidney transplantation, or an eGFR <15 mL/min/1.73 m 2 sustained for ≥30 days.
There were not enough events to evaluate the risk of renal death (placebo, n=5; INVOKANA®, n=2). INVOKANA® is not indicated to reduce the risk of renal death.
§RRR was calculated using the following formula: 100 x (1–HR).
||In all glycemic control trials of INVOKANA®, hypoglycemia was defined as any event, regardless of symptoms, in which biochemical hypoglycemia was documented (any glucose value ≤70 mg/dL) or any hypoglycemic episode was considered severe. Severe hypoglycemia was defined as an event consistent with hypoglycemia in which the patient required the assistance of another person to recover, lost consciousness, or experienced a seizure (regardless of whether biochemical documentation of a low glucose value was obtained).1

AEs=adverse events; CV=cardiovascular; DKA=diabetic ketoacidosis; DKD=diabetic kidney disease; GMI=genital mycotic infection; RRR=relative risk reduction; SGLT2i=sodium-glucose co-transporter 2 inhibitor; T2D=type 2 diabetes.

References: 1. INVOKANA® [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals, Inc. 2. Jardiance® [prescribing information]. Ridgefield, CT: Boehringer lngelheim Pharmaceuticals, Inc. 3. Farxiga® [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP. 4. Steglatro TM [prescribing information]. Whitehouse Station, NJ: Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. 5. Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295-2306. Supplementary appendix available at: doi:10.1056/NEJMoa1811744. 6. Mahaffey KW, Jardine MJ, Bompoint S, et al. Canagliflozin and cardiovascular and renal outcomes in type 2 diabetes mellitus and chronic kidney disease in primary and secondary cardiovascular prevention groups. Circulation. 2019;140(9):739-750.